伯恩斯坦研究机构宣布，将百济神州的投资评级从"与大市同步"提升至"跑赢大市"，同时将其目标股价从362美元大幅上调至414美元。这一调整反映了该机构对百济神州未来发展前景的积极预期。
此次评级上调基于对公司核心业务增长潜力的重新评估，目标价的上调幅度达到14.4%，显示出分析师对该公司价值的认可。伯恩斯坦认为，百济神州在创新药物研发和商业化方面展现出的优势，有望推动其业绩实现超预期表现。
伯恩斯坦研究机构宣布，将百济神州的投资评级从"与大市同步"提升至"跑赢大市"，同时将其目标股价从362美元大幅上调至414美元。这一调整反映了该机构对百济神州未来发展前景的积极预期。
此次评级上调基于对公司核心业务增长潜力的重新评估，目标价的上调幅度达到14.4%，显示出分析师对该公司价值的认可。伯恩斯坦认为，百济神州在创新药物研发和商业化方面展现出的优势，有望推动其业绩实现超预期表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.